The SAFE Act and Peptide Research: What You Need to Know in 2026

On December 9, 2025, bipartisan legislation was introduced in both chambers of Congress that could reshape the compounding pharmacy landscape — and by extension, the broader peptide market. The Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025 (H.R. 6509 in the House, S. 3794 in the Senate) proposes new restrictions on compounding pharmacies, expanded FDA inspection authority, and reporting requirements that would affect how compounded peptides reach patients and researchers.

The bill arrives at a moment of extraordinary tension in peptide regulation. On one side, the FDA has spent two years restricting access to peptides through Category 2 designations and aggressive enforcement actions. On the other, HHS Secretary Robert F. Kennedy Jr. has publicly stated his intention to reverse most of those restrictions. The SAFE Drugs Act adds a third force to this dynamic — congressional legislation that could override both the FDA’s current position and Kennedy’s announced policy direction.

This article breaks down what the SAFE Drugs Act contains, how it fits into the current regulatory landscape, and what it means for anyone involved in peptide research.

What Is the SAFE Drugs Act?

The SAFE Drugs Act — formally the Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025 — was introduced in the House by Representatives Rudy Yakym (R-IN) and Andre Carson (D-IN), and in the Senate by Senator Jim Banks (R-IN) with Senator Martin Heinrich (D-NM) as cosponsor.

The bill amends the Federal Food, Drug, and Cosmetic Act (FDCA) to expand FDA oversight of compounding pharmacies and outsourcing facilities. While it does not mention peptides specifically, its provisions would directly affect how compounded peptide formulations are produced, distributed, and monitored.

The Six Key Provisions

1. The 20-Unit Monthly Cap

The most impactful provision for the compounding industry: the bill would prevent compounding pharmacies from producing more than 20 units per month of any drug that is “essentially a copy” of a commercially available product, unless the formulation is tailored to an individual patient’s specific needs.

This targets mass compounding — the practice of producing large quantities of compounds that closely replicate FDA-approved drugs. The primary target appears to be compounded GLP-1 agonists (semaglutide and tirzepatide analogs), but the language is broad enough to apply to any compounded peptide that has a commercially available equivalent.

2. Interstate Reporting Requirements

Pharmacies, facilities, or physicians shipping more than 20 compounded prescriptions per year containing active ingredients found in commercially available drugs to out-of-state patients would be required to submit annual reports to the FDA. Hospital pharmacies compounding for their own patients are exempt.

3. Pre-Compounding Inspections for Outsourcing Facilities

Under Section 503B of the FDCA, outsourcing facilities are allowed to compound drugs without individual prescriptions. The SAFE Drugs Act would require the FDA to conduct a pre-compounding inspection before any outsourcing facility begins work on a new drug product. Additionally, “large-scale outsourcing facilities” — defined as those compounding more than 100 drug products in a calendar year — would face mandatory biennial re-inspections.

4. Fee Restructuring

The bill eliminates the current statutory $15,000 base establishment fee for 503B outsourcing facilities and replaces it with a fee “deemed appropriate by the Secretary.” This effectively removes any fee cap and delegates fee-setting authority to HHS — a change that could either reduce or significantly increase the financial burden on outsourcing facilities, depending on how HHS exercises this discretion.

5. Codification of “Essentially a Copy”

The bill formally codifies the legal definition of what constitutes an “essential copy” of a commercially available drug. This is significant because the “essentially a copy” standard has been the subject of ongoing litigation between compounding pharmacies and the FDA, and a statutory definition would provide a clearer — and potentially more restrictive — legal framework than current case-by-case adjudication.

6. Removal of Registration Exemptions

Current law provides certain registration exemptions for outsourcing facilities. The SAFE Drugs Act would eliminate these exemptions, requiring full registration compliance from all compounding operations.

Current Status of the Bill

As of March 9, 2026, the SAFE Drugs Act remains in committee in both chambers:

• House (H.R. 6509): Referred to the House Committee on Energy and Commerce
• Senate (S. 3794): Read twice, referred to the Committee on Health, Education, Labor, and Pensions (HELP)

No committee hearings or markups have been scheduled as of this writing. No floor votes have occurred in either chamber. The bill has not been signed into law and does not currently have the force of regulation.

Who Supports the SAFE Drugs Act?

The bill has drawn support from patient safety organizations, including the Partnership for Safe Medicines, which issued a formal letter of support. Supporters argue that the bill addresses real risks:

• The FDA has reported over 1,000 adverse event reports linked to compounded GLP-1 drugs
• Compounding pharmacies operating at scale without adequate FDA oversight present quality control risks
• Mass compounding of copies of FDA-approved drugs undermines the regulatory framework designed to ensure drug safety and efficacy

Critics have noted that the bill also aligns with the commercial interests of pharmaceutical companies like Novo Nordisk (manufacturer of semaglutide/Ozempic/Wegovy) and Eli Lilly (manufacturer of tirzepatide/Mounjaro/Zepbound), both of which have been aggressively pursuing legal action against compounders producing generic versions of their drugs.

Who Opposes It?

The Alliance for Pharmacy Compounding (APC), the Aimed Alliance, and various patient access organizations have raised concerns about the bill. Their objections center on several points:

• The 20-unit monthly cap could restrict patient access to medically necessary compounded medications, particularly for patients who cannot tolerate or afford FDA-approved alternatives
• The reporting requirements impose significant administrative burden on small pharmacies
• The bill is viewed by critics as primarily serving pharmaceutical industry interests rather than patient safety
• The fee restructuring — giving HHS unlimited discretion to set fees — could be used to make outsourcing facility operation prohibitively expensive

Representative Diana Harshbarger (R-TN) and Representative Buddy Carter (R-GA) — the only two licensed pharmacists in the U.S. House — had previously introduced the Drug Shortage Compounding Patient Access Act (H.R. 5316) in September 2025, which took the opposite approach: expanding, rather than restricting, compounding access.

The Regulatory Collision: SAFE Act vs. RFK Jr. vs. FDA

To understand the SAFE Drugs Act’s significance, you have to see it in the context of two other major regulatory forces at work simultaneously.

Force 1: The FDA’s Category 2 Restrictions

Beginning in late 2023, the FDA placed 19 peptides on its Category 2 restricted list, barring compounding pharmacies from preparing them. These included widely used research and clinical peptides such as BPC-157, TB-500, CJC-1295, Ipamorelin, and Semax. The restrictions eliminated a primary legal pathway for patients and clinicians to access these compounds.

Force 2: RFK Jr.’s Reclassification Announcement

On February 27, 2026, HHS Secretary Kennedy announced on The Joe Rogan Experience that approximately 14 of the 19 restricted peptides would be moved from Category 2 back to Category 1, restoring compounding eligibility. Kennedy characterized the restrictions as counterproductive, stating they had “created the black market” by pushing patients toward unregulated sources. Read our full coverage of the RFK Jr. announcement.

Force 3: The SAFE Drugs Act

The SAFE Drugs Act operates on a different axis entirely. Rather than targeting specific compounds (like the FDA’s Category 2 list), it targets the infrastructure of compounding itself — imposing volume caps, inspection requirements, and reporting obligations that could constrain compounding pharmacies regardless of which specific peptides are permitted.

This creates a paradox: even if RFK Jr. successfully moves 14 peptides back to Category 1, the SAFE Drugs Act could limit how much of those peptides compounding pharmacies can actually produce and distribute. Restoring a compound to Category 1 removes the prohibition on compounding it, but a 20-unit monthly cap could make large-scale compounding economically nonviable.

How Does This Affect Peptide Research?

It is important to distinguish between compounded pharmaceuticals and research peptides. The SAFE Drugs Act primarily targets:

• 503A compounding pharmacies that prepare patient-specific formulations with a physician’s prescription
• 503B outsourcing facilities that produce compounded drugs without individual prescriptions

Research peptide suppliers — companies that sell peptides labeled “for research use only” for laboratory and scientific investigation — operate under a different regulatory framework. The SAFE Drugs Act’s compounding restrictions do not directly apply to research chemical sales.

However, the broader regulatory environment affects the entire peptide ecosystem in several ways:

• Supply chain effects: Restrictions on compounding can shift demand toward research peptide suppliers, increasing scrutiny on that segment of the market
• Enforcement attention: Legislative activity around peptides generally increases FDA awareness and enforcement activity across all peptide-related businesses, as demonstrated by the Peptide Sciences shutdown in March 2026
• Quality standards: Greater regulatory attention tends to raise the bar for quality verification and documentation across the market
• Research access: If compounding restrictions reduce clinical access to peptides, academic and independent researchers may face additional hurdles in sourcing reference materials

Timeline: Peptide Regulation 2023–2026

Date	Event	Impact
Late 2023	FDA places 19 peptides on Category 2	Compounding pharmacies barred from preparing these compounds
March 2024	Eli Lilly files ITC complaint against 12 peptide vendors	First major pharma enforcement action against peptide sellers
September 2024	FDA removes 5 peptides from Category 2	AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank removed
January 2025	ITC General Exclusion Order on tirzepatide imports	Blanket import ban regardless of shipper
June 2025	FDA raids Amino Asylum	Criminal enforcement against grey-market supplier
July 2025	Sen. Tuberville letter to HHS on peptide enforcement	Congressional pushback on restrictions begins
September 2025	H.R. 5316 (Drug Shortage Compounding Patient Access Act) introduced	Pro-access compounding bill from pharmacist Representatives
September 2025	FDA issues 50+ warning letters to peptide businesses	Largest coordinated enforcement wave
Late 2025	Tailor Made Compounding guilty plea, $1.79M forfeiture	Criminal consequences for compounding violations
November 2025	Rep. Harshbarger letter to HHS on peptide enforcement discretion	Additional congressional pressure for access
December 9, 2025	SAFE Drugs Act introduced (H.R. 6509 / S. 3794)	New restrictions on compounding infrastructure
February 27, 2026	RFK Jr. announces peptide reclassification on JRE #2461	14 peptides expected to return to Category 1
March 6, 2026	Peptide Sciences shuts down	Major grey-market supplier exits voluntarily

What to Watch For

The peptide regulatory landscape in 2026 is being shaped by three competing forces simultaneously. Here is what researchers should monitor:

The SAFE Drugs Act’s Progress

The bill is in committee in both chambers. Key milestones to watch: committee hearings, markup sessions, floor votes. If the bill advances, pay attention to amendments — the 20-unit cap and fee restructuring provisions are likely to be the most contested elements.

The FDA’s Formal Response to RFK Jr.’s Announcement

As of March 9, 2026, no formal regulatory action has been published confirming the reclassification of peptides from Category 2 to Category 1. The FDA must publish changes through proper administrative channels (Federal Register notices, updated bulks list). Podcast statements — even from the HHS Secretary — do not constitute regulatory action.

Enforcement Activity

Regardless of legislative and executive developments, the FDA continues to pursue enforcement actions against peptide sellers. The Peptide Sciences shutdown and the ongoing wave of warning letters suggest that enforcement priorities have not changed, even as policy direction shifts.

The Drug Shortage Compounding Patient Access Act (H.R. 5316)

This competing bill takes the opposite approach to the SAFE Drugs Act, seeking to expand compounding access. Whether one, both, or neither bill advances will determine the legislative trajectory for peptide compounding.

The Bottom Line for Researchers

The SAFE Drugs Act is one piece of a complex regulatory puzzle. For those conducting peptide research, several practical takeaways emerge:

• Regulatory uncertainty persists. Multiple competing forces — FDA enforcement, executive policy signals, and congressional legislation — are pulling in different directions simultaneously. No single outcome is guaranteed.
• Source quality matters more than ever. In an environment of heightened scrutiny, third-party verified, HPLC-tested research materials from transparent suppliers are essential for maintaining research integrity.
• Stay informed on official channels. Monitor the FDA’s official bulks list, Federal Register publications, and congressional bill trackers (congress.gov) rather than relying on media summaries or podcast announcements.
• Diversify supply chains. The exit of major suppliers like Peptide Sciences and the ongoing regulatory churn make single-source dependence risky for long-term research programs.

Suppliers like NorthPeptide continue to provide HPLC-verified research peptides — including BPC-157, NAD+, Sermorelin, Retatrutide, and TB-500 — with third-party testing and batch-specific certificates of analysis, supporting the rigorous documentation standards that the current regulatory environment demands.

We will continue to update this article as the SAFE Drugs Act progresses through Congress and as the FDA publishes formal regulatory determinations on peptide reclassification.

Written by NorthPeptide Research Team

---

Disclaimer: This article is for informational and educational purposes only. Nothing in this article constitutes legal advice, medical advice, or a recommendation regarding the purchase or use of any substance. NorthPeptide supplies research peptides strictly for laboratory and research use. These products are not intended for human consumption. Researchers are responsible for complying with all applicable federal, state, and local regulations governing the purchase and use of research materials. For legal questions regarding peptide compounding or the SAFE Drugs Act, consult a qualified attorney.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Obesity Medicine Association	2024	Position Statement FAQ	Compounded peptides — regulatory framework and clinical guidance	PMC11369382
Starr et al.	2010	Review	FDA regulation of dietary supplements and adverse event reporting requirements	PMID 20032973
Maughan	2019	Review	Current regulatory guidelines and resources to support dietary supplement research in the US	PMC6513729
Nussinov et al.	2025	Review	Regulatory guidelines for analysis of therapeutic peptides and proteins	PMC11806371
Lau & Dunn	2018	Review	Comprehensive review on advances in peptide drug development and design	PMC6566176
Li et al.	2025	Review	Advance in peptide-based drug development — delivery platforms and therapeutics	PMC11880366
Gorman	2016	Commentary	FDA draft guidances on compounding pharmacies — regulatory limitations	PMC4959613